| __timestamp | Ionis Pharmaceuticals, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 100244000 |
| Thursday, January 1, 2015 | 322292000 | 29674000 |
| Friday, January 1, 2016 | 344320000 | 14917000 |
| Sunday, January 1, 2017 | 374644000 | 14118000 |
| Monday, January 1, 2018 | 414604000 | 8737000 |
| Tuesday, January 1, 2019 | 466000000 | 6900000 |
| Wednesday, January 1, 2020 | 535000000 | 6248000 |
| Friday, January 1, 2021 | 643000000 | 12312000 |
| Saturday, January 1, 2022 | 833000000 | 19721000 |
| Sunday, January 1, 2023 | 899625000 | 31283000 |
| Monday, January 1, 2024 | 901530000 |
In pursuit of knowledge
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and MannKind Corporation have demonstrated contrasting trajectories in their R&D investments. Ionis Pharmaceuticals has consistently increased its R&D spending, growing by approximately 272% from 2014 to 2023. This commitment underscores their dedication to pioneering new therapies and maintaining a competitive edge. In contrast, MannKind Corporation's R&D expenses have fluctuated, peaking in 2014 and then declining by about 69% by 2023. This divergence highlights the varied strategic approaches within the industry. As Ionis continues to invest heavily in R&D, MannKind's more conservative spending may reflect a focus on optimizing existing products. These trends offer a glimpse into the strategic priorities shaping the future of biopharmaceutical innovation.
Comparing Innovation Spending: Eli Lilly and Company and Ionis Pharmaceuticals, Inc.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Summit Therapeutics Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
R&D Insights: How Verona Pharma plc and MannKind Corporation Allocate Funds
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds